文献速递技术与安全介入US

微泡造影剂:新方向

Microbubble Agents: New Directions.
PubMed 文献 · Ultrasound Med Biol · 2020-03-11

微泡超声造影剂已使用数十年,其在广泛诊断应用中的安全性和有效性已充分确立。影像技术的进步正推动分子成像、三维成像和超分辨率成像等技术的发展,同时新造影剂也在针对这些需求进行研发。在治疗应用方面也取得显著进展,近期临床试验显示微泡可递送药物跨越血脑屏障并进入实体瘤。

要点

  • 微泡超声造影剂的安全性和有效性已在广泛诊断应用中充分确立。
  • 影像技术进步正推动分子成像、三维成像和超分辨率成像等新技术发展。
  • 近期临床试验显示微泡治疗应用可递送药物跨越血脑屏障并进入实体瘤。

临床应用与阅片要点

  • 微泡超声造影剂的安全性和有效性已在广泛诊断应用中充分确立。
  • 影像技术进步正推动分子成像、三维成像和超分辨率成像等新技术发展。
  • 近期临床试验显示微泡治疗应用可递送药物跨越血脑屏障并进入实体瘤。

局限性

  • 新型造影剂的开发面临若干挑战,尤其涉及监管框架。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Microbubble ultrasound contrast agents have now been in use for several decades and their safety and efficacy in a wide range of diagnostic applications have been well established. Recent progress in imaging technology is facilitating exciting developments in techniques such as molecular, 3-D and super resolution imaging and new agents are now being developed to meet their specific requirements. In parallel, there have been significant advances in the therapeutic applications of microbubbles, with recent clinical trials demonstrating drug delivery across the blood-brain barrier and into solid tumours. New agents are similarly being tailored toward these applications, including nanoscale microbubble precursors offering superior circulation times and tissue penetration. The development of novel agents does, however, present several challenges, particularly regarding the regulatory framework. This article reviews the developments in agents for diagnostic, therapeutic and "theranostic" applications; novel manufacturing techniques; and the opportunities and challenges for their commercial and clinical translation.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Stride E, Segers T, Lajoinie G, et al. Microbubble Agents: New Directions. Ultrasound Med Biol. 2020. PMID: 32169397. doi:10.1016/j.ultrasmedbio.2020.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。